白质改变的临床试验
总计2372个结果
-
AstraZenecaICON plc尚未招聘转甲状腺素蛋白淀粉样变性 | ATTR-CM | ATTRv-PN | ATTR | ATTR-混合 | hATTR
-
UNC Lineberger Comprehensive Cancer Center招聘中
-
Virginia Commonwealth UniversityFoundation for Physical Therapy, Inc.; Children's Hospital Foundation完全的
-
Wake Forest University Health SciencesNational Institute on Aging (NIA)完全的
-
BaycrestSunnybrook Health Sciences Centre未知
-
Centre Hospitalier Universitaire, Amiens招聘中
-
Dr. Sandra E Black招聘中
-
Akira SekikawaNational Institute on Aging (NIA)招聘中
-
Institut National de la Santé Et de la Recherche...University College, London完全的
-
Augusta UniversityGeorgia Rehabilitation Institute招聘中
-
Fondation Ophtalmologique Adolphe de Rothschild终止
-
The First Hospital of Jilin UniversityNational Natural Science Foundation of China未知
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)完全的小肠腺癌 | III 期小肠腺癌 AJCC v8 | IIIA 期小肠腺癌 AJCC v8 | IIIB 期小肠腺癌 AJCC v8 | IV 期小肠腺癌 AJCC v8 | 壶腹腺癌 | Vater 壶腹癌 AJCC v8 III 期 | IIIA 期 Vater 壶腹癌 AJCC v8 | IIIB 期 Vater 壶腹癌 AJCC v8 | Vater 壶腹癌 AJCC v8 IV 期美国
-
St. Luke's Hospital, Chesterfield, MissouriWashington University School of Medicine终止
-
University of Alabama at BirminghamTroy University完全的
-
Deciphera Pharmaceuticals LLC终止
-
University Children's Hospital, Zurich完全的
-
BioMed Valley Discoveries, Inc终止晚期实体瘤 | MAP2K1基因突变 | BRAF基因突变 | MEK突变 | BRAF 基因改变 | 丁酮变更 | MAP2K1 基因改变 | MAP2K2基因突变 | MAP2K2 基因改变美国
-
Fore Biotherapeutics招聘中
-
Janssen Scientific Affairs, LLC批准上市晚期癌症和 FGFR 基因改变
-
Qilu Pharmaceutical Co., Ltd.招聘中
-
Kafrelsheikh University未知
-
3H (Suzhou) Pharmaceuticals Co., Ltd.尚未招聘
-
Foundation MedicineJohns Hopkins University; Memorial Sloan Kettering Cancer Center; University of California, San... 和其他合作者完全的
-
United States Army Research Institute of Environmental...United States Department of Defense完全的
-
Northumbria University完全的
-
Novartis Pharmaceuticals完全的
-
Children's Hospital of PhiladelphiaNational Institute of Neurological Disorders and Stroke (NINDS)完全的